5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer.
10.1016/j.gpb.2018.06.002
- Author:
Ji ZHANG
1
,
2
;
Xiao HAN
3
;
Chunchun GAO
3
;
Yurong XING
4
;
Zheng QI
5
;
Ruijuan LIU
1
,
2
;
Yueqin WANG
1
,
2
;
Xiaojian ZHANG
1
,
2
;
Yun-Gui YANG
6
,
7
,
8
;
Xiangnan LI
9
;
Baofa SUN
6
,
7
,
10
;
Xin TIAN
1
,
11
Author Information
1. Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, China.
3. Sino-Danish College, University of Chinese Academy of Sciences, Beijing 100049, China.
4. Physical Examination Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
5. Department of Anesthesiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
6. Sino-Danish College, University of Chinese Academy of Sciences, Beijing 100049, China
7. CAS Key Laboratory of Genomic and Precision Medicine, School of Future Technology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China
8. Institute of Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China.
9. Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: lxn-2000@163.com.
10. Institute of Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: sunbf@big.ac.cn.
11. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, China. Electronic address: tianx@zzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
5-Hydroxymethylcytosine;
5hmC-Seal;
Biomarker;
Cell-free DNA;
Lung cancer
- MeSH:
5-Methylcytosine;
analogs & derivatives;
blood;
Biomarkers, Tumor;
blood;
genetics;
Carcinoma, Non-Small-Cell Lung;
blood;
diagnosis;
genetics;
Case-Control Studies;
Circulating Tumor DNA;
blood;
DNA Methylation;
Epigenomics;
Female;
Humans;
Lung Neoplasms;
blood;
diagnosis;
genetics;
Male;
Middle Aged
- From:
Genomics, Proteomics & Bioinformatics
2018;16(3):187-199
- CountryChina
- Language:English
-
Abstract:
Non-small-cell lung cancer (NSCLC), the most common type of lung cancer accounting for 85% of the cases, is often diagnosed at advanced stages owing to the lack of efficient early diagnostic tools. 5-Hydroxymethylcytosine (5hmC) signatures in circulating cell-free DNA (cfDNA) that carries the cancer-specific epigenetic patterns may represent the valuable biomarkers for discriminating tumor and healthy individuals, and thus could be potentially useful for NSCLC diagnosis. Here, we employed a sensitive and reliable method to map genome-wide 5hmC in the cfDNA of Chinese NSCLC patients and detected a significant 5hmC gain in both the gene bodies and promoter regions in the blood samples from tumor patients compared with healthy controls. Specifically, we identified six potential biomarkers from 66 patients and 67 healthy controls (mean decrease accuracy >3.2, P < 3.68E-19) using machine-learning-based tumor classifiers with high accuracy. Thus, the unique signature of 5hmC in tumor patient's cfDNA identified in our study may provide valuable information in facilitating the development of new diagnostic and therapeutic modalities for NSCLC.
